-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Cullinan Oncology and Taiho Pharmaceutical jointly announced that they have reached an agreement whereby Taiho will acquire Cullinan Pearl, a subsidiary of Cullinan Oncology, and jointly develop and commercialize the oral irreversible EGFR inhibitor CLN-081/TAS6417 with Cullinan Oncology for the treatment of non-small cell lung canc.
Worldwide, approximately 9 million people are diagnosed with NSCLC each year, and approximately 38,000 of them carry EGFR exon 20 insertion mutatio.
CLN-081/TAS6417 is an oral tyrosine kinase inhibitor targeting EGFR activating mutatio.
Image source: Cullinan Oncology's official website
Under the terms of the agreement, Taiho will acquire Cullinan Pearl, which owns the global development rights for CLN-081/TAS6417 outside of Japan, and will pay Cullinan Oncology an upfront payment of $275 million, as well as regulatory milestones related to EGFR exon 20 insertion mutant NSC.
"We are delighted to add CLN-081/TAS6417 to the R&D pipeline," said .
References:
[1] Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho's Acquisition of Cullinan Pea.
